Predicting cerebral infarction and transient ischemic attack in healthy individuals and those with dysmetabolism: a machine learning approach combined with routine blood tests.

Journal: Scientific reports
PMID:

Abstract

Ischemic cerebral infarction is the most prevalent type of stroke, causing significant disability and death worldwide. Transient ischemic attack (TIA) is a strong predictor of subsequent stroke. Individuals with dysmetabolism, such as hypertension, hypercholesterolemia, and diabetes, are at increased risk for cerebral infarction (CI) and TIA. In resource-limited settings, diagnosing CI and TIA can be particularly difficult due to a lack of advanced imaging and specialized expertise. Therefore, we aim to develop a simple, convenient, blood-based approach that could assist clinicians in diagnosing CI and TIA, especially in regions where advanced imaging or stroke-specific expertise is limited. All study subjects were patients admitted to the First Hospital of Xiamen University and healthy check-up populations between January 2018 and September 2023. This study employed five machine learning methods alongside 21 blood routine indicators, 30 blood biochemical indicators, age, and gender to construct predictive models for CI and TIA in both healthy individuals and those with dysmetabolism. The Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) served as the metric to assess the comprehensive predictive capability of the models. Subsequently, the SHAP package was employed for model interpretation. Extreme Gradient Boosting (XGBoost) outperforms other models in all predictive models. In the models predicting CI and TIA among healthy, the AUC is 0.9958 (0.9947-0.9969) and 0.9928 (0.9899-0.9951), respectively. Among the nine shared key features of the two models are indicators of glucose metabolism, lipid metabolism, and liver metabolism. In the models for predicting CI and TIA among patients with hypertension, hypercholesterolemia, diabetes, and those with all three metabolic disorders combined, the AUCs ranged from 0.6990 to 0.8591. We found that the indicators K significantly contributed to predict CI and TIA from those with dysmetabolism. Additionally, metabolic-related indicators, such as glucose (GLU) and high-density lipoprotein cholesterol (HDL-C), are ranked highly among the top ten contributing features. XGBoost performed the best in all models. It can effectively differentiate CI and TIA from healthy and dysmetabolic patients by combining blood routine and blood biochemical indicators. Moreover, it can also differentiate CI from TIA. Although any suspicious findings from this model would still require confirmatory imaging, the simplicity and low cost of blood-based testing may offer a practical adjunct for clinicians-particularly in areas lacking advanced imaging or extensive stroke expertise-and could facilitate earlier diagnostic decision-making.

Authors

  • Yunyun Yang
    Guangdong Provincial Key Laboratory of Chemical Measurement and Emergency Test Technology, Guangdong Provincial Engineering Research Center for Ambient Mass Spectrometry, Institute of Analysis, Guangdong Academy of Sciences (China National Analytical Center, Guangzhou), Guangzhou, 510070, China.
  • Lindan Huang
    Department of Laboratory Medicine, Xiamen Key Laboratory of Genetic Testing, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, Fujian, China.
  • Ying Gu
    Department of Radiation Oncology, Jinling Hospital, Nanjing, Jiangsu, 210002, China.
  • Zhicheng Wang
    Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Shuai Liu
    Graduate School of Chinese Academy of Traditional Chinese Medicine, Beijing, China.
  • Qun Chen
    Shanghai United Imaging Healthcare Co., Ltd, Shanghai 201807, People's Republic of China.
  • Wanshan Ning
    Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Bioinformatics and Molecular Imaging Key Laboratory, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
  • Guolin Hong
    Department of Laboratory Medicine, Xiamen Key Laboratory of Genetic Testing, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, Fujian, China. xmhgl9899@xmu.edu.cn.